PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas

British Journal of Cancer

Volumn 97, Issue 6, 2007, Pages 809-817

  Gozgit, J M ^a   Pentecost, B T ^b   Marconi, S A ^c   Ricketts Loriaux, R S J ^c   Otis, C N ^c   Arcaro, K F ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b WADSWORTH CENTER   (United States)

^c BAYSTATE MEDICAL CENTER   (United States)

Author keywords

Akt; Breast cancer; PLD1; Rapamycin; TMX2 28 cells

Indexed keywords

CYTOKERATIN; CYTOKERATIN 17; CYTOKERATIN 5; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHOLIPASE D1; PROTEIN KINASE B;

ARTICLE; BREAST CARCINOMA; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA MICROARRAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA, COMPLEMENTARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; ONCOGENE PROTEIN V-AKT; PHOSPHOLIPASE D; PROTEIN KINASES; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 34548561788     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603926     Document Type: Article

References (30)

1. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203: 661-671
2. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11: 5319-5328
3. Carraway H, Hidalgo M (2004) New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6: 219-224
4. Chen J, Fang Y (2002) A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol 64: 1071-1077
5. Chen Y, Rodrik V, Foster DA (2005) Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene 24: 672-679
6. Chen Y, Zheng Y, Foster DA (2003) Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 25: 3937-3942
7. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN (2005) Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 85: 154-159
8. Fang Y, Park IH, Wu AL, Du G, Huang P, Frohman MA, Walker SJ, Brown HA, Chen J (2003) PLD1 regulates mTOR signaling and mediates Cdc42 activation of S6K1. Curr Biol 13: 2037-2044
9. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J (2001) Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294: 1942-1945
10. Fasco MJ, Amin A, Pentecost BT, Yang Y, Gierthy JF (2003) Phenotypic changes in MCF-7 cells during prolonged exposure to tamoxifen. Mol Cell Endocrinol 206: 33-47
11. Foster DA, Xu L (2003) Phospholipase D in cell proliferation and cancer. Mol Cancer Res 1: 789-800
12. Gozgit JM, Nestor KM, Fasco MJ, Pentecost BT, Arcaro KF (2004) Differential action of polycyclic aromatic hydrocarbons on endogenous estrogen-responsive genes and on a transfected estrogen-responsive reporter in MCF-7 cells. Toxicol Appl Pharmacol 196: 58-67
13. Gozgit JM, Pentecost BT, Marconi SA, Otis CN, Wu C, Arcaro KF (2006) Use of an aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer. Mol Cancer Res 12: 905-913
14. Hidalgo M, Rowinsky EK (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686
15. Joseph T, Wooden R, Bryant A, Zhong M, Lu Z, Foster DA (2001) Transformation of cells overexpressing a tyrosine kinase by phospholipase D1 and D2. Biochem Biophys Res Commun 289: 1019-1024
16. Liu G, Loraine AE, Shigeta R, Cline M, Cheng J, Valmeekam V, Sun S, Kulp D, Siani-Rose MA (2003) NetAffx: Affymetrix probesets and annotations. Nucleic Acids Res 31: 82-86
17. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de RM, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374
18. Noh DY, Ahn SJ, Lee RA, Park IA, Kim JH, Suh PG, Ryu SH, Lee KH, Han JS (2000) Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett 161: 207-214
19. Osborne CK (1998) Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51: 227-238
20. Pentecost BT, Bradley LM, Gierthy JF, Ding Y, Fasco MJ (2005) Gene regulation in an MCF-7 cell line that naturally expresses an estrogen receptor unable to directly bind DNA. Mol Cell Endocrinol 238: 9-25
21. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406: 747-752
22. Rodrik V, Zheng Y, Harrow F, Chen Y, Foster DA (2005) Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol Cell Biol 25: 7917-7925
23. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386
24. Ruggero D, Pandolfi PP (2003) Does the ribosome translate cancer? Nat Rev Cancer 3: 179-192
25. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253-262
26. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874
27. Thomas GV (2006) mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev 16: 78-84
28. Tokunaga E, Kimura Y, Oki E, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Baba H, Maehara Y (2006) Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 118: 284-289
29. Uchida N, Okamura S, Nagamachi Y, Yamashita S (1997) Increased phospholipase D activity in human breast cancer. J Cancer Res Clin Oncol 123: 280-285
30. Zhong M, Shen Y, Zheng Y, Joseph T, Jackson D, Foster DA (2003) Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 302: 615-619